Clinical Trial Results:
A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0, dated 30-Mar-06, and
Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific, version 1.0, dated 12-Apr-06
Summary
|
|
EudraCT number |
2005-005099-33 |
Trial protocol |
BE GB IT |
Global completion date |
04 Mar 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA165-026_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.